



## **Opportunity Statement**

INTELDAS is not following the traditional investment route. Instead, we are inviting visionary entrepreneurs, strategic partners, and key influencers to explore unique opportunities in **M&A**, **licensing**, **re-licensing**, **and acquisition**. As we prepare to bring **the first and only Al-driven demand system** to market, we are actively seeking collaborators who recognize the **transformative impact** of this innovation in the legal Al space. **Now is the time to shape the future of injury claim valuation**.

#### **Business Models for:**

- Market Penetration
- Revenue Generation
- Exit Plan

## The Momentum of First-Mover Growth: Why INTELDAS Expands Itself

Some innovations don't just enter a market—they **create a new industry standard**. INTELDAS isn't waiting to compete; it's defining the future of **injury claim valuation**, and early adopters will shape the next era.

Organic growth is inevitable. Attorneys don't stay silent about tools that help them secure bigger settlements, faster approvals, and airtight valuations. When a firm realizes it has been leaving money on the table, it seeks a solution—and INTELDAS is the only one that exists.

# Why This Growth is Self-Sustaining:

Attorneys talk—referrals happen naturally, driving viral adoption.
✓ Tech solutions fuel adoption—Al solves attorneys' #1 problem: undervaluation,
uncovering hidden medical value.
✓ Compounding expansion—As attorneys upgrade tiers, relicense, and integrate
into SaaS platforms, revenue scales exponentially.

The legal Al sector isn't just evolving—it's **waiting for leadership**. INTELDAS is not only filling that void; it's setting the standard. This growth isn't forced—it's **unleashed**.

## Market Strategy & Revenue Model

## 1. Direct Licensing to Attorneys

- 3,000 subscribers at various tiers generate between \$18M and \$72M ARR.
- Attorneys subscribe at different pricing levels, unlocking higher-tier services as they see increased value.
- Revenue potential scales rapidly as users move up tiers.

3,000 Subscribers	MRR	ARR
Tier 1 (\$499 per month per subscriber)	\$1.497 Million	\$17.964 Million
Tier 2 \$(750 per month per subscriber)	\$2.250 Million	\$27.000 Million
Tier 3 (\$1,049 per month per subscriber)	\$3.147 Million	\$37.764 Million
<b>Tier 4</b> (\$1,099 per month per subscriber)	\$5.997 Million	\$71.964 Million

### 2. Licensing to SaaS Companies

- One SaaS partner alone could generate \$6M to \$12.6M ARR.
- Licensing to 10 SaaS companies could push ARR beyond \$154M.
- Each additional company expands market penetration exponentially.

#### 3. Exit Strategy

INTELDAS presents a **lucrative exit opportunity** due to its **unique market position**, **unrivaled technology stack**, **and scalable revenue potential**. We anticipate acquisition interest from:

- SaaS companies & legal tech firms seeking Al-powered expansion.
- Private equity firms looking for high-margin, high-growth investments.
- Strategic buyers aiming to strengthen their legal and medical Al portfolios.

#### **Projected Exit Timeline: 18-24 months**

- Exit Valuation: Driven by ARR & EBITDA multiples, aligning with 10x 15x SaaS industry standards.
- Low Estimate: \$62.8M exit valuation (Tier 1 adoption).
- High Estimate: \$431M+ exit valuation (Tier 4 adoption).

# Financial Projections for Direct Licensing to Attorneys at Exit Based on Lowest and Highest Tier-Level Scenarios:

		Tier 1 Model	Tier 4 Model
Revenue		\$17,964,000 ARR	\$71,964,000 ARR
Estimated EBITDA Margin		30-40% (Conservative estimate for a high-margin SaaS platform)	35-45% (Due to economies of scale and higher tier pricing)
EBITDA Calculation		\$17,964,000 x 35% = <b>\$6,287,400</b>	\$71,964,000 x 40% = <b>\$28,785,600</b>
EBITDA Multiple		SaaS companies in similar markets have recently sold at multiples ranging from 10x to 15x EBITDA, given their recurring revenue model and growth potential.	Based on the same market multiples of 10x to 15x.
Exit Valuation	Low Estimate (10x EBITDA)	\$6,287,400 x 10 = <b>\$62,874,000</b>	\$28,785,600 x 10 = <b>\$287,856,000</b>
	High Estimate (15x EBITDA)	\$6,287,400 x 15 = <b>\$94,311,000</b>	\$28,785,600 x 15 = <b>\$431,784,000</b>

# **Competitive Advantage & Market Position**

- First-Mover Advantage No competing technology provides INTELDAS' proprietary Al-driven claim valuation capabilities.
- ✓ Massive Market Opportunity Solving a \$40B+ undervaluation problem, directly impacting injury settlements.
- ☑ Scalable, High-Margin SaaS Low overhead, predictable revenue, and high adoption rates.
- ✓ Multiple Exit Strategies M&A, private equity, strategic buyout, or potential IPO.

# Why Partner with INTELDAS?

INTELDAS presents an unprecedented opportunity to be part of **the next evolution in legal Al technology**. This isn't just an investment—it's a chance to lead a **market-wide** 

transformation. Early adopters will set the rules of the game, and INTELDAS is leading the way.

We invite you to **join us in reshaping the legal industry** and unlocking the full potential of injury claim valuation and **let's build the future together.** 

Watch/Scan to learn how INTELDAS delivers high-growth, high-return potential.

Join Dr. Frank Liberti, founder of INTELDAS, as he reveals the **extraordinary ROI potential** of this **first-mover AI legal tech**. This exclusive presentation dives into how INTELDAS is positioned for **high-margin scalability**, **rapid market adoption**, **and a strategic exit plan**—making it a **prime investment opportunity**.

Watch now to see why **industry leaders**, **strategic partners**, **and M&A decision-makers** are seizing the chance to be part of this **high-growth**, **high-return innovation** before the window closes.





# Dr. Frank Liberti – Visionary in Legal AI

Founder of INTELDAS, Dr. Frank Liberti is revolutionizing injury claim valuation with first-mover AI technology. With a background in medicallegal analysis and clinical forensics, he has spent his career solving the \$40B undervaluation problem, giving attorneys the tools to maximize settlements and eliminate claim underpricing.





Dr. Frank Liberti - Founder

f\_liberti@msn.com

727-520-3961







